Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies

Current combination therapies elicit high response rates in B cell malignancies, often using CD20 antibodies as the backbone of therapy. However, many patients eventually relapse or develop progressive disease. Therefore, novel CD20 antibodies combining multiple effector mechanisms were generated. T...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:MAbs
Autori principali: Evers, Mitchell, Ten Broeke, Toine, Jansen, J.H. Marco, Nederend, Maaike, Hamdan, Firas, Reiding, Karli R., Meyer, Saskia, Moerer, Petra, Brinkman, Iris, Rösner, Thies, Lebbink, Robert Jan, Valerius, Thomas, Leusen, Jeanette H.W.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2020
Soggetti:
Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7531568/
https://ncbi.nlm.nih.gov/pubmed/32744145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2020.1795505
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi